Extraction form for project: Screening for Glaucoma in Adults - 1 of 2

Design Details

1. Study design

Arms

Arm NameArm Description
A. Latanaprostene bunod 0.006%
B. Latanaprostene bunod 0.012%
C. Latanaprostene bunod 0.024%
D. Latanaprostene bunod 0.04%
E. Latanaprost 0.005%

Sample Characteristics

1. N
A. Latanaprostene bunod 0.006%
B. Latanaprostene bunod 0.012%
C. Latanaprostene bunod 0.024%
D. Latanaprostene bunod 0.04%
E. Latanaprost 0.005%
Total
2. Baseline population
A. Latanaprostene bunod 0.006%
B. Latanaprostene bunod 0.012%
C. Latanaprostene bunod 0.024%
D. Latanaprostene bunod 0.04%
E. Latanaprost 0.005%
Total

Outcomes

TypeDomainSpecific measurement (i.e., tool/definition/specific outcome)PopulationsTimepoints
CategoricalVision disorderIntraocular pressure (IOP), change from baseline, day 28
  • All Participants
  • 28 days
ContinuousHarm/adverse eventWithdrawal due to adverse events
  • All Participants
  • end of study

Risk of Bias Assessment

1. Random assignment
2. Allocation concealed
3. Groups similar at baseline
4. Eligibility criteria specified
5. Blinding: outcome assessors or data analysts
6. Intention-to-treat analysis
7. Reporting of attrition, contamination, etc.
8. Differential loss to followup or overall high loss to followup
9. Appropriate analysis including cluster correlation
10. Funding source
11. Randomization adequate?
12. Allocation concealment adequate?
13. Groups similar at baseline?
14. Eligibility criteria specified?
15. Outcome assessors masked?
16. Care provider masked?
17. Patient masked?
18. Attrition and withdrawals reported?
19. Loss to followup differential/ high?
20. People analyzed in the groups in which they were randomized?
21. Quality

Results

Categorical


Vision disorder (Intraocular pressure (IOP), change from baseline, day 28)

All Participants
Descriptive StatisticsBetween Arm Comparisons
A. Latanaprostene bunod 0.006%B. Latanaprostene bunod 0.012%C. Latanaprostene bunod 0.024%D. Latanaprostene bunod 0.04%E. Latanaprost 0.005%
C. Latanaprostene bunod 0.024%
vs.
E. Latanaprost 0.005%

D. Latanaprostene bunod 0.04%
vs.
E. Latanaprost 0.005%
28 days
IOP
Difference (95% CI)
p value
Within Arm ComparisonsNet Comparisons
A. Latanaprostene bunod 0.006%B. Latanaprostene bunod 0.012%C. Latanaprostene bunod 0.024%D. Latanaprostene bunod 0.04%E. Latanaprost 0.005%
C. Latanaprostene bunod 0.024%
vs.
E. Latanaprost 0.005%
D. Latanaprostene bunod 0.04%
vs.
E. Latanaprost 0.005%

Continuous


Harm/adverse event (Withdrawal due to adverse events)

All Participants
Descriptive StatisticsBetween Arm Comparisons
A. Latanaprostene bunod 0.006%B. Latanaprostene bunod 0.012%C. Latanaprostene bunod 0.024%D. Latanaprostene bunod 0.04%E. Latanaprost 0.005%
end of study
Percentage
Mean Difference (MD)
95% CI low (MD)
95% CI high (MD)
SD (MD)
p value (MD)
Within Arm ComparisonsNet Comparisons
A. Latanaprostene bunod 0.006%B. Latanaprostene bunod 0.012%C. Latanaprostene bunod 0.024%D. Latanaprostene bunod 0.04%E. Latanaprost 0.005%